Similar to breast cancer, where up to 50% of ERα-positive tumors are hormonally resistant de-novo, these trials in ovarian cancer suggest that inhibiting estrogen signaling on a receptor level has some efficacy; however it is not enough to produce a strong clinical response. This evidence concerns the gene ESR1 and breast carcinoma.